Aruvant gains Rare Pediatric status for sickle cell disease candidate ARU-1801
Clinical-stage USA-based biotech Aruvant Sciences says that the US Food and Drug Administration has g... See more »
Aruvant is a biopharmaceutical company that develops and commercializes gene therapies for the treatment of hematological diseases. Read more
Aruvant is a biopharmaceutical company that develops and commercializes gene therapies for the treatment of hematological diseases. Read more
CEO
William Chou
No recent acquisitions found related to Aruvant
No recent funding data found related to Aruvant
No recent investments found related to Aruvant
Viaduktstrasse 8
Basel, Basel-City4051
Driving Directions »